2nd Circ. Backs Lilly Win In Drug Label Warning MDL

Law360, New York (November 21, 2012, 5:00 PM EST) -- The Second Circuit upheld a victory for Eli Lilly & Co. on Tuesday in a suit in multidistrict litigation claiming it failed to warn of diabetes risks linked to an antipsychotic treatment, saying Rhode Island courts would likely adopt a doctrine governing drugmakers' duty to warn.

A three-judge panel upheld a New York district court's summary judgment ruling in favor of Lilly. The suit was part of multidistrict litigation alleging Lilly failed to reveal Zyprexa's harmful side effects, including weight gain and diabetes, in an aggressive...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.